These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 17716172)

  • 1. Don't bury your head in the nanostuff.
    Clift R
    Nanomedicine (Lond); 2007 Jun; 2(3):267-70. PubMed ID: 17716172
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanotoxicology and nanomedicine: making hard decisions.
    Linkov I; Satterstrom FK; Corey LM
    Nanomedicine; 2008 Jun; 4(2):167-71. PubMed ID: 18329962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A framework for designing transgenic crops--science, safety and citizen's concerns.
    König A
    Nat Biotechnol; 2003 Nov; 21(11):1274-9. PubMed ID: 14595351
    [No Abstract]   [Full Text] [Related]  

  • 4. NANOtechnology: untold promise, unknown risk.
    Consum Rep; 2007 Jul; 72(7):40-5. PubMed ID: 17632953
    [No Abstract]   [Full Text] [Related]  

  • 5. Nanomedicine and risk: further perspectives.
    Moore R
    Med Device Technol; 2007 Oct; 18(6):28-9. PubMed ID: 18078179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bt crop risk assessment in the Netherlands.
    Knols BG; Dicke M
    Nat Biotechnol; 2003 Sep; 21(9):973-4. PubMed ID: 12949550
    [No Abstract]   [Full Text] [Related]  

  • 7. UK field-scale evaluations answer wrong questions.
    Chassy B; Carter C; McGloughlin M; McHughen A; Parrott W; Preston C; Roush R; Shelton A; Strauss SH
    Nat Biotechnol; 2003 Dec; 21(12):1429-30. PubMed ID: 14647318
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential pitfalls of nanotechnology in its applications to medicine: immune incompatibility of nanodevices.
    Shetty RC
    Med Hypotheses; 2005; 65(5):998-9. PubMed ID: 16023299
    [No Abstract]   [Full Text] [Related]  

  • 9. Concern-driven integrated approaches for the grouping, testing and assessment of nanomaterials.
    Landsiedel R
    Environ Pollut; 2016 Nov; 218():1376-1380. PubMed ID: 26586635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthy challenges.
    Nat Nanotechnol; 2007 Aug; 2(8):451. PubMed ID: 18654332
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of the occupational, consumer and environmental exposure to engineered nanomaterials used in 10 technology sectors.
    Nowack B; Brouwer C; Geertsma RE; Heugens EH; Ross BL; Toufektsian MC; Wijnhoven SW; Aitken RJ
    Nanotoxicology; 2013 Sep; 7(6):1152-6. PubMed ID: 22783888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indefinite particles.
    Toumey C
    Nat Nanotechnol; 2008 Jul; 3(7):372-3. PubMed ID: 18654552
    [No Abstract]   [Full Text] [Related]  

  • 13. Environmental, health and safety issues: Nanoparticles in the real world.
    McCall MJ
    Nat Nanotechnol; 2011 Oct; 6(10):613-4. PubMed ID: 21979234
    [No Abstract]   [Full Text] [Related]  

  • 14. Nano-safety studies urged in China.
    Qiu J
    Nature; 2012 Sep; 489(7416):350. PubMed ID: 22996527
    [No Abstract]   [Full Text] [Related]  

  • 15. The risks of nanotechnology.
    Williams D
    Med Device Technol; 2005 Nov; 16(9):6, 9-10. PubMed ID: 16438441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pitfalls of growing nanomaterials.
    Shiekh FA; Farooq O; Mian SH; Bautista RL; Arja SB; Andrabi KI
    Nanomedicine (Lond); 2016 Jul; 11(13):1635-8. PubMed ID: 27348020
    [No Abstract]   [Full Text] [Related]  

  • 17. Environmentally responsible development of nanotechnology.
    Roco MC
    Environ Sci Technol; 2005 Mar; 39(5):106A-112A. PubMed ID: 15787356
    [No Abstract]   [Full Text] [Related]  

  • 18. Using ECRI Institute's health technology hazard self-assessment tool--a case study.
    Health Devices; 2012 Sep; 41(9):303-4. PubMed ID: 23444665
    [No Abstract]   [Full Text] [Related]  

  • 19. What is nanomedicine?
    Freitas RA
    Nanomedicine; 2005 Mar; 1(1):2-9. PubMed ID: 17292052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-tier tests insufficient for GMO risk assessment.
    Lang A; Lauber E; Darvas B
    Nat Biotechnol; 2007 Jan; 25(1):35-6; author reply 36-7. PubMed ID: 17211390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.